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Background: An advanced stage, centrally localized invasive tumor is a major cause of
sudden death in lung cancer patients. Currently, chemotherapy, radiotherapy, laser
ablation, or surgical resection if possible are the available state-of-the-art treatments
but none of these guarantee remedy or long-term relief and are often associated with fatal
complications. Allowing localized chemotherapy, by direct and confined drug delivery only
at the tumor site, could be a promising option for preoperative down staging or palliative
therapy. Here we report the localized and targeted application of intra tumor delivery of
chemotherapeutics using a novel device based on the principle of electrospray.
Methods: C57BL/6J mice were injected with Lewis lung carcinoma cells subcutaneously.
After 15 days, the animals were anesthetized and the tumors were exposed by skin
incision. Tumors were electrosprayed with 100 µg cisplatin on days 0 and 2, and tumor
volumes were measured daily. Animals were sacrificed on day 7 after the first electrospray
and tumors were analyzed by immunohistochemistry.
Results: In this proof-of-concept study, we report that the tumor volume was reduced by
81.2% (22.46 ± 12.14 mm3) after two electrospray mediated Cisplatin deliveries, while the
control tumor growth, at the same time point, increased by 200% (514.30 ± 104.50 mm3).
Moreover, tunnel and Caspase-3 positive cells were increased after Cisplatin electrospray
compared to other experimental groups of animals.
Conclusion: Targeted drug delivery by electrospray is efficient in the subcutaneous
mouse model of lung cancer and offers a promising opportunity for further development
toward its clinical application.
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INTRODUCTION
It is estimated that by 2030 lung cancer will be the 6th most
common cause of death, affecting 1.6 million people worldwide. It
is the most common cancer that leads to death in men (17%) and
the third most common in women (13%) (Siegel et al., 2020).
Smoking has been identified as the major cause of lung cancer
with the highest incidence rate reported in North America,
Europe, and East Asia. Moreover, with increasing populations
now living in polluted metropolitan regions globally, the
incidence of lung cancer is also increasing, particularly in non-
smokers (Cheng et al., 2016; De Groot et al., 2018). Despite
advances in diagnosis and therapy, the 5-year survival rate of
patients with lung cancer is only 18% (Lu et al., 2019). Due to
invasive tumor growth, 30% of all lung cancer patients suffer from
a central airway obstruction (CAO), which is one of the major
problems physicians face when caring for these patients. Patients
develop respiratory distress and post stenotic pneumonia leading
to suffocation and death (Ernst et al., 2004). Most patients who
develop CAO are inoperable with no real or long lasting safe
therapeutic options (Ernst et al., 2004; Lee et al., 2015). There is
therefore a compelling need for successful lung cancer treatment.
Recent advances, in the treatment of lung cancer are promising
and several targeted therapies have been tested and reported on
with mixed results. Targeted approaches based on
immunotherapy are very expensive and have low efficiency
(Thunnissen et al., 2014; Reck et al., 2016). This low efficiency
is because current approaches rely on surface marker recognitions
that are situated on the tumor cells, yet the therapeutics are
administered systemically (Petrosyan et al., 2012; Chan and
Hughes, 2015). Furthermore, heterogeneity of the tumor
surface markers and the complexity of tumor stroma makes
targeting approaches even more difficult. Additionally,
selective delivery of chemotherapeutic drugs, only to tumor
cells, is a major challenge in cancer chemotherapy. Various
attempts have therefore been made that mainly rely on
nanoparticle-based technology (Xin et al., 2017). The
nanomedicine-based targeting approaches depend either on
passive drug targeting using liposomes and polymers, or active
drug targeting by ligands that are attached to drugs, acting as
homing devices for binding to receptors expressed on the surface
of the tumor cells. Many studies were performed, testing both
methods in various kinds of tumors in different organs with mild
effects (Lammers et al., 2008; Lammers et al., 2012). It is worth
mentioning that the systemic route of administration was applied
in all these studies. Interestingly, injecting chemotherapeutical
drugs, locally, into the invasive lung tumor have been attempted
(Celikoglu et al., 2010; Hohenforst-Schmidt et al., 2013); however,
no randomized clinical studies have been reported to elucidate its
safety and efficacy. Therefore, a promising approach could be to
deliver therapeutic agents locally, at the site of the tumor, with
drug delivery methods that utilize a physical force to achieve
direct intracellular delivery gaining maximal therapeutic effect
and avoiding systemic side effects. There have been attempts
made for the local delivery of genes and chemotherapeutics in the
past using physical methods like sonoporation, a method based
on ultrasound in a mouse tumor model (Yuh et al., 2005; Iwanaga
et al., 2007); however, due to technical limitations, this method
could never be applied for clinical application. Another method
of localized chemotherapy using electric pulses termed as
electrochemotherapy is currently used for treating primary
skin tumors (Caracò et al., 2013), metastatic skin tumors
(Macri et al., 2014; Cabula et al., 2015), and head and neck
tumors (Mevio et al., 2012; Bertino et al., 2016). Although
electrochemotherapy has shown promising results when
applied on external tumors, it has never been used for internal
visceral tumors and invasive lung tumors. Therefore, a concept of
local intracellular drug delivery that can be easily applied within
the bronchus lumen, to target the invasive tumor to arrest tumor
growth, could be a promising approach. We introduce the novel
concept―the electrospray mediated targeted drug delivery
method―using Cisplatin, to potentially treat invasive tumors
in the bronchus. Electrospray, also known as
electrohydrodynamic jetting, is based on the principle of
Coulomb repulsion; under the influence of high voltage the
flowing liquid breaks into small droplets that are then
accelerated toward a counter electrode, which is in contact
with the target tissue during delivery (Hradetzky et al., 2012;
Boehringer et al., 2018). The accelerated droplets easily penetrate
inside the cells facilitating drug delivery. The technical design and
the proof-of-concept both in vitro and in vivo were demonstrated
using electrospray mediated eGFP gene transfer (Boehringer
et al., 2018). In the current study, we investigate the effect of
electrospray mediated localized chemotherapy using Cisplatin on




Cell lines and drugs: For in vitro and in vivo studies, Lewis lung
carcinoma cells (LLC cells (ATCC; United States) were obtained
as generous gift from Prof. Adrian Ochsenbein (Department of
Biomedical Research University of Bern Switzerland). LLC cells
were grown in DMEM medium containing 10% fetal bovine
serum (Life technologies, United States). Cisplatin (Sigma
Aldrich, United States) was used at a concentration of 1 nM
for in vitro experiments and at a 3.3 mM (1 mg/ml) concentration
for in vivo application. For in vitro experiments Cisplatin was
diluted in 370 mM sucrose. For the in vivo study Cisplatin was
used at a concentration of 0.2 mg in the total volume of 100 µl.
Tandem Mass Spectrometry of Cisplatin: The DNA hexamer
5′-TTCGGC-3′ (Microsynth, Balgach, Switzerland) was
dissolved in water to obtain a 1 mM stock solution. Cisplatin
samples were collected before and after the electrospray process
and incubated over night at 37°C with equimolar amounts of the
DNA hexamer. The incubated samples were diluted to 25 µM in a
solvent mixture containing water, acetonitrile, and triethylamine
at a ratio of 49:49:2. The mass spectrometric analysis was
performed on a LTQ Orbitrap XL instrument (Thermo Fisher
Scientific, Bremen, Germany) equipped with a nano-electrospray
ionization source. Analyses were performed in the negative ion
mode. The triply charged cisplatin adduct with m/z 669 was
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selected as the precursor ion and subjected to collision-induced
dissociation (CID) using nitrogen as the collision gas.
In vitro electrospray on Lewis lung carcinoma cells: Lewis lung
carcinoma (LLC) cells were grown in DMEM media (Life
Technologies, United States) in 10% FCS (Life Technologies,
United States) and 1% Penicillin/Streptomycin (Life
Technologies, United States). For in vitro experiments, 24 well
plates (BD Biosciences, United States) were coated with purified
bovine collagen solution (PureCol Biomatrix, United States) at a
concentration of 60 μg/ml 1 × 105 cells were plated in the center of
the collagen coated wells, suspended in culture media in a volume
of 10 µL. To facilitate attachment, cells were incubated for 30 min
at 37°C and 5% CO2 and then replenished with 500 µL growth
medium. Cells grew as a monolayer in the center of the plate and
were placed under the electrodes during electrospray procedure.
Before electrospray was performed, cells were checked for
homogenous distribution in the center of the well under the
microscope.
In vitro electrospray: The electrospray procedure was
performed using the prototype device previously developed
and described (Boehringer et al., 2018). For all in vitro
purposes, Cisplatin was used at a concentration of 1 nM
dissolved in 370 mM sucrose. The electrospray parameters
were as follows; 3 kV voltage, working distance (distance
between tip of capillary and the target cells) 4 mm, flowrate
20 μL/min, and s volume of 25 µL of chemotherapeutical drug
per suspension. All parameters are based on previous a study
(Boehringer et al., 2018).
In vitro electrospray was performed four times, with 25 µL per
treatment, and with a 30 s lag between each electrospray. After
electrospray, cells were incubated for 10 min, media was
replenished, and cells were placed in the incubator. After 24 h
of incubation, Annexin V/PI staining and flow cytometry
measurements were performed as described below. Three
independent experiments were performed in triplicate.
Cisplatin uptake In vitro: Three different concentrations of
Cisplatin were used (0.01 mg/ml, 0.1 mg/ml and 1 mg/ml), either
in-vitro electrospray or conventional (i.e., without electrospray),
and Cisplatin treatment was performed on LLC cells with 75 µL
Cisplatin. Cells were divided in two sets and different washing
procedures were performed. In one set, the cells were washed
twice with Phosphate-buffered saline (PBS, 500 µL each) and
twice with water (500 µL each), whereas washing was omitted for
the second set. As controls, untreated LLC cells were analyzed,
and the concentration of the used Cisplatin stock solution was
measured for quantification of the recoveries. Ten minutes after
electrospray, samples were digested in 0.5 ml 65% nitric acid
(HNO3) at 95 C for 2 h and then diluted 1:20 with water. Samples
without the washing step and the Cisplatin stock solution were
further diluted at 1:500 with 3% HNO3. Gold (Au) was added as
the internal standard and Platinum was analyzed by ICP-MS
(inductively coupled plasma mass spectrometry) with a Varian
820-MS (Varian, Santa Clara, CA,United States), without the
application of a collision gas to the sampler cone. Three
independent experiments were performed in triplicate.
Annexin PI staining and analysis by FACS: Annexin V/PI
staining was done using the FITC annexin V apoptosis detection
kit with PI (Biolegend, United States), following the manufactures
protocol. Flow cytometry measurements were done with the LSR
II SORP H274 system (BD Biosciences, United States). A 488 nm
blue laser was used for excitation. For emission measurements
two filters were used, wavelength 585/15 was used for PI and
Alexa Fluor 488 filter 525/50 was used for Annexin V. Data was
analyzed with the single cell analysis software FLOWJO (FlowJo
LLC, BD Bioscience, Canada). The positive control for the
necrotic cell was made by freezing cell suspension in -80 °C
for 20 min. The positive control for the apoptotic cell was done by
incubating cells in 4% PFA for 30 min. Three independent
experiments were performed in triplicate.
In vivo Electrospray
Animals: C57BL/6J adult male mice were obtained from Janvier
labs (France). The animals were kept ad libitum. Experiments
were performed in accordance with the standards of the
European Convention of Animal Care. The study protocol was
approved by the Cantonal and University of Bern Animal Study
Committee (BE 99/14).
Subcutaneous Tumor model: Lewis lung carcinoma (LLC)
cells were grown in DMEM media (Life technologies,
United States) in 10% FCS (Life technologies, United States).
The animals were injected with 2 × 106 LLC cells suspended in
100 µL of 1xPBS, subcutaneously, on both flanks. Tumor volume
was measured using a caliper and experiments were performed
after 15 days, as explained below.
Analgesia and Anesthesia: Mice were injected with
buprenorphine (0.1 mg/kg) subcutaneously (sc) 30 min
before surgery. For anesthesia, Midazolam (Dormicum)
5 mg/kg, Medetomidine (Domitor) 0.5 mg/kg, and Fentanyl
(Fentanyl-Janssen) 0.05 mg/kg were administered
intraperitoneally (0.05 ml per 20 gm mice). To protect the
eyes of the mice, Bepanthen (5% Dexpanthenol) was
applied before the procedure.
Electrospray mediated chemotherapy: The animals were
divided into five groups with n  5 in each group; (a) Control
group (no drug), (b) Cisplatin local injection (no electrospray),
(c) NaCl local injection (no electrospray), (d) Electrospray only,
and (e) Cisplatin + electrospray. Analgesia and anesthesia were
administered as described and the surgical procedure was
performed. The tumor was exposed by a skin incision and the
electrode of the electrospray device was placed on the tumor
surface for electrospray. For in vivo electrospray, the following
parameters were applied: voltage 3 kV, with working distance of
4 mm, and flowrate of 100 μL/min. Each tumor was
electrosprayed four times at four different places, with 25 µL
of the drug for each spray, and with a 30 s lag time between the
spray. After electrospray, the skin was sutured using VICRYL 4.0
(Ethicon, Inc. United States). Mice were injected with antagonist
subcutaneously (sc) for reversal of the anesthesia as described
above. Analgesic buprenorphine (0.1 mg/kg) (sc) was
administered daily. A second electrospray was performed two
days later. Tumor volumes were measured every day using a
caliper. Seven days after the first electrospray, the animals were
euthanized by CO2 inhalation and tumors were excised and
collected for analysis.
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Assessment
Caliper measurements of subcutaneous tumors: Mice were
anesthetized by inhaling isoflurane in a glass box. Mice tumor
volumes were evaluated by measuring the height, width, and
length of the tumor using a caliper. The tumor shape was
considered to be a rotary symmetric ellipsoid, and the volume
was calculated using the formula VOLUME
(3.14*Height*Width*Length)/6 (Kersemans et al., 2013). The
calculated volume of the first day was normalized to 100%,
representing an initial relative tumor volume, and all
subsequent volumes were divided by the initial tumor volume
representing the fraction of tumor volume in %, to demonstrate
the dynamic change in tumor volume.
Immunohistochemistry (IHC): Tumors were fixed in 4%
neutral buffered formalin, embedded in paraffin. IHC staining
was performed on a Leica BOND RX automated immunostainer
(Leica Biosystems). Thin sections (1–2 µm) of tumors were pre-
treated by boiling at 100°C in citrate buffer, pH 6.0. Sections were
then stained at room temperature in Bond primary antibody
diluent (Leica Biosystems) for 30 min using the rabbit anti-mouse
cleaved caspase-3 (Asp175) (clone 5A1E, Cell Signaling
Technologies, catalog no. 9664), dilution 1:100. Visualization
was performed using the Bond Polymer Refine DAB Detection
kit (Leica Biosystems, catalog no. DS9800) according to the
manufacturer’s instructions. Images were captured using the
3D HISTECH slide scanner. Analysis of IHC was performed
by two blinded surgical pathologists (C.M.S. and F.B.).
Tunnel assay: Tunnel assay was performed on paraffin
embedded tissue using the Tunnel assay kit HRP-DAB
(Abcam, United States), following the protocol provided. Total
stained cells per area at high power field in three separate fields
were counted using image J (Image J 1.51n, NIH, United States).
Statistics: In vitro experiments were done in triplicate and all
the experiments were performed three times. Data is presented as
mean ± SEM, and the student t test for in vitro data, or multiple
comparison using ANOVA and Bonferroni correction, were
performed using Graph Pad prism 7.0 (Graphpad software,
United states).
RESULTS
Electrospray Application of Cisplatin Does
Not Change the Drug’s Mechanism of
Action
A potential cellular target of cisplatin is DNA. To study the effect
of the electrospray process on the activity of the drug, cisplatin
samples collected before and after electrospray were incubated
with the DNA hexamer 5′-TTCGGC-3′ and subsequently
analyzed by tandem mass spectrometry. Activation of selected
precursor ions in the gas-phase, results in cleavage of the
phosphate backbone, thus, generating sequence-specific
fragment ions (Wu, 2004) (Schürch, 2016). The triply charged
DNA-cisplatin adducts ((TTCGGC + cisPt)3−, m/z 668.6) were
selected as the precursor ions. Mass spectrometric data indicates
identical adduct formation in both samples treated with cisplatin
solution before (Figure 1A) and after electrospray (Figure 1B).
Both spectra show the peaks of fragment ions that indicate the
binding of cisplatin to the vicinal guanine nucleobases (Nyakas et
al., 2009). Binding of cisplatin promotes the cleavage of the 3′-C-
O bond adjacent to the GG base pair and the subsequent release of
cytidine monophosphate (w1
− fragment ion at m/z 306.05) from
the 3′-end. The complementary fragment is observed as the
doubly charged (TTCGG + cisPt)2− ion at m/z 850.13. Besides
these main fragment ions, indicative of adduct formation of
cisplatin with the oligonucleotide, the binding of the drug is
reflected by further platinum-containing ions generated by the
loss of nucleobases from either end of the oligonucleotide (e.g.
(TCGGC + cisPt)2− at m/z 891.63 and (TTCG + cisPt)2− at m/z
685.61).
The preferred binding site within the DNA hexamer was
found to be the vicinal guanine nucleobases, which is
consistent with previous studies. Consequently, the
electrospray process neither affects the ability of cisplatin to
form adducts, nor changes the preferred binding site on a
DNA oligonucleotide.
Electrospray Increases Intracellular Uptake of
Cisplatin in vitro
Electrospray increases intracellular uptake of Cisplatin in vitro:
Cisplatin 1 mg/ml was used for experiments. To quantify the
amount of intracellular Cisplatin uptake after electrospray the
LLC cells were treated with 75 μg, 7.5 µg of 0.75 µg (75 µl of
volume) of Cisplatin delivered by electrospray or the cells were
incubated with the same concentration of Cisplatin (conventional
cell culture). The percentage of intracellular platinum was
(412.2*10−6% ± 48.317*10−6%) when cells were incubated with
Cisplatin at a concentration of 1,000 μg/ml, however when
electrospray mediated Cisplatin, a delivery was performed, and
the concentration increased to (1.033*10−3% ± 113*10−6%) (p ˂
0.001) (Figure 2A). Moreover, intracellular concentration of
platinum was significantly increased after electrospray
mediated delivery (16.5 ± 3.9%) (p ˂ 0.001) (Figure 2B).
Decreased Cell Viability After in vitro
Electrospray
To quantify cell viability and cell death via apoptosis or necrosis
24 h after the electrospray experiment, Annexin/PI staining was
performed on LLC cells. Cisplatin at a 1 nM concentration
significantly reduced cell viability compared to the controls
(p  0.012). Cell viability further decreased from 82.4 ± 4.4%
(Cisplatin no electrospray) to 23.8 ± 3.5%, when Cisplatin was
electrosprayed (p < 0.0001). Interestingly, electrospray itself also
decreased cell viability to 46.2 ± 3.5% compared to the controls
(p < 0.0001) (Figure 3A). It is known that Cisplatin causes cell
death via apoptosis. Cisplatin treatment alone led to 8.7 ± 4.8%
apoptotic cells. However, when Cisplatin was electrosprayed, the
percentage of apoptotic cells increased to 36.5 ± 5.3% (p < 0.005)
(Figure 3B). Moreover, 24 h later, the necrotic cell population
also increased with electrosprayed Cisplatin 36.70 ± 0.1% vs.
25.63 ± 2.23% electrospray only, and 7.8 ± 0.5% cisplatin only,
respectively (p < 0.0005) (Figure 3C). A gating strategy for the
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FIGURE 1 | MS/MS spectra obtained by collision-induced dissociation of the triply charged platinated hexadeoxynucleotide precursor ions (m/z 669), which
basically show the identical fragment ions and give evidence for adduct formation ( unchanged drug activity). Adduct formation and DNA binding sites by naïve Cisplatin
(A) Cisplatin after electrospray (B).
FIGURE 2 | Intracellular uptake of Cisplatin; percentage of delivered Cisplatin that entered the cells (A) and amount of intracellular Cisplatin (B) after electrospray
mediated Cisplatin delivery in vitro. Data presented as mean ± SEM, p < 0.05*, p < 0.001 **, p < 0.0001 ***.
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cells was used for annexin V/PI staining control cells (Figure 4A),
cells treated with Cisplatin (Figure 4B), electrospray only
(Figure 4C), and Electrospray mediated Cisplatin delivery
(Figure 4D).
Electrospray Mediated Chemotherapy
Significantly Reduces Tumor Volume in vivo
For the in vivo experiment, Electrospray was performed at day 0
and day 2, and the subcutaneous tumor growth dynamics were
measured daily after in vivo electrospray using a caliper. Three
days after the first electrospray application, the tumor volume
decreased by 42.9% (38 ± 7.3 mm3) of the initial volume in
response to Cisplatin electrospray, whereas the tumor size in the
control group (no treatment) was 200% increased (487 ±
24 mm3) compared to the initial tumor volume. There was an
increase of 16.2% (247 ± 15 mm3) for the Cisplatin only group
and a 27% increase (191 ± 22 mm3) of initial tumor volume for
the electrospray only group. The second treatment was performed
on this day and the tumor volume showed a gradual decrease after
electrospray mediated Cisplatin treatment compared to the
control groups. At day seven, the group receiving the Cisplatin
FIGURE 3 | Effect of Cisplatin alone and electrospray Cisplatin delivery on cell viability (A), necrosis (B) and apoptosis (C). Graph showing Flow cytometry gating
strategy for Annexin V/PI. Data presented as mean ± SEM, p < 0.05*, p < 0.001**, p < 0.0001***.
FIGURE 4 | Gating strategy for annexin V/PI staining for invitro experiment. Control cells (A), Cispatin treatment (B), electrospray only (C), electrospray mediated
Cisplatin (D).
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electrospray had the tumor volume reduced by 81.2% of the
original volume (22.4 ± 12.1 mm3) (Figure 5A) (p < 0.0001). The
Cisplatin only group had a decrease of 14.4% (168.6 ± 3.9 mm3)
(p < 0.05) and the electrospray only group had a 15.4% (170.6 ±
39.2 mm3) reduction of the initial tumor volume (p < 0.05).
The tumor volume at day seven in the control group increased
by 200% (542 ± 110.0 mm3) (control group), and 310% (1,000 ±
51 mm3) in the NaCl group. The data of the three treated groups
is visualized and presented in Figure 5B.
Electrospray Mediated Chemotherapy
Increases Caspase-3 Positive Cells in
Tumor
Increased Capase-3 positive cells were seen in the tumor when
Cisplatin was electrosprayed, 44 ± 15%, compared to when
Cisplatin was injected into the tumor, 21 ± 1%. Interestingly,
fewer positive cells, 15 ± 12%, were observed in the untreated
control tumor, when NaCl was injected in the tumor, 21 ± 1%,
and when only electrospray was performed, 7.5 ± 1.4%
(Figure 6A). In accordance, increased tunnel positive cells
were observed; after electrospray mediated Cisplatin 116 ±
18.2%, compared to 73 ± 8.9% after Cisplatin injection.
Furthermore, fewer positive cells were observed when NaCl
was injected, 14 ± 3%, and 16.4 >% ± 3.14% when only
electrospray was performed. The number of positive cells in
the absolute control tumors were 14.2 ± 3.5% cells per high
power field by photomicroscopy quantification (Figure 6B). Data
is presented as the number of cells per high power field.
DISCUSSION
In the current study, we demonstrate the efficacy of electrospray
mediated targeted chemotherapy in a mouse model of lung
cancer. Electrospray mediated chemotherapy of Cisplatin is
efficient and reproducible and we observed a reduced tumor
size after two applications of localized electrospray mediated
chemotherapy. Moreover, electrospray mediated Cisplatin
induced apoptosis as demonstrated by tunnel positive and
Caspase-3 positive cells.
To test for purity and stability of the drug substance during
routine drug production, a high performance liquid
chromatography (HPLC) is performed for every drug used
(Rasmussen et al., 2007). Electrospray is based on the
principle of Coulomb repulsion using high voltage (Boehringer
et al., 2018), therefore, tandemmass spectrometry was carried out
to test the effect of the electrospray process on the stability of
Cisplatin. Interestingly, no difference was observed, neither in the
ability of Cisplatin to form adducts, nor for changes at the
preferred binding site on a DNA oligonucleotide. Following
this encouraging result, the effect of electrospray on intra
cellular accumulation of Cisplatin and cell death was studied
in vitro. Intracellular concentration of Cisplatin after electrospray
mediated transfer was significantly increased compared to
incubation only. Although the exact mechanism of
electrospray mediated drug delivery is still under investigation,
based on our previous study, we speculate that an alteration in the
cell membrane permeability under influence of droplets that are
generated and accelerated by an electric field (Boehringer et al.,
2018), leads to increased intracellular Cisplatin concentration.
This increased intracellular accumulation causes cell apoptosis
after electrospray mediated Cisplatin delivery in vitro.
Attempts have been made for targeted drug delivery and such
studies demonstrate a demand for localized and targeted
chemotherapy (Stirland et al., 2013; Senapati et al., 2018).
Physical methods like electroporation-based chemotherapy is
now applied in clinical practice but are limited to external
tumors in the skin, or the head and neck region (Seyed Jafari
et al., 2018; Campana et al., 2019). Until now however, no attempt
to apply electroporation mediated drug delivery to visceral organs
has been reported. Electroporation relies on the application of
high voltage, directly on the target organ (Gehl et al., 1999;
Graybill and Davalos, 2020), It will therefore generate high
electrical current pulses due to the conductivity of the treated
tissue, causing power dissipation within the treated area.
Moreover, the limiting factor could be the technical difficulties
faced in developing a device that can be used to safely apply high
voltage inside the body. Therefore, we developed the electrospray-
basedmethod where high voltage is applied at the tip of the needle
to create spray, and no voltage is applied directly to the target
FIGURE 5 | Tumor volume measured in different experimental groups
(A). Tumor volume of the three treated groups for better visualization of
data (B).
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organ (Hradetzky et al., 2012). The electrospray process does not
involve the application of high voltage directly at the target organ
and is independent of the size of the electrode. The accelerated
droplets penetrate the target area probably by making the
membrane more permeable. Electrospray is a unique device
and is not similar to nebulized inhalers. Nebulizing a
chemotherapeutic agent is not targeted, moreover distribution
of a nebulized drug is not equal and homogeneous. The
electrospray device could, to some extent, be compared to
needle free injections (Ravi et al., 2015), with the difference
however, that the power source is neither integrated within
the device, nor is the drug enclosed inside the electrospray
device for a long time as seen with needleless injections.
A significant reduction in the tumor volume was observed
after the application of electrospray mediated chemotherapy to
the subcutaneous tumor mouse model in vivo. As mentioned, the
exact mechanism of electrospray is not yet known; nevertheless, a
reduction in tumor size was also observed when only electrospray
was applied to the tumors, without any chemotherapy agent. This
is an additive benefit of the method while targeting tumors. We
can only speculate that this effect was due to increased cellular
permeability due to electrospray. Moreover, an increase in
apoptotic cells after electrospray mediated Cisplatin delivery
confirms intracellular entry and also the known mechanism of
action of Cisplatin (Siddik, 2003). However, the cell death due to
electrospray only without Cisplatin, is significantly lower
indicating that electrospray might reduce the tumor by other
possible mechanisms that are yet to be explored. Our goal is to
develop and modify a device that can be used within the working
channel of the bronchoscope as this would enable targeted
delivery via a minimally invasive method. For this purpose, a
miniaturized device design has been elaborated (Fiave et al., 2013)
and in vivo application is planned. Novel treatment approaches
for tumor treatment, like immunotherapy, is one promising
approach and it depends on the presence of binding receptors
on the tumor surface, but is administered systemically. The
heterogeneous distribution and orientation of the receptors on
the surface of the tumor is, however, a limiting factor for its
FIGURE 6 | Histological images of caspase 3 staining, and the quantification of caspase 3 positive cells (A). Scale bar 100 µm. Images of tunnel positive cells and
quantification of tunnel positive cells (B), scale bar 2,000 µm (entire tumor) and 100 µm for inset images, data is presented as number of cells high power field. Data
presented as mean ± SEM, p < 0.05*, p < 0.001**, p < 0.0001 ***.
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success. Electrospray based administration of immunotherapy,
directly to the tumor, might help enhance its efficiency and
probably reduces the cost of treatment. Similarly, gene therapy
approaches for tumor treatment are hindered due to safe and
efficient vectors, based on our previous data (Boehringer et al.,
2018); we envision the use of electrospray for gene therapy
targeting tumors. The electrospray technique is promising and
can be used for targeted chemotherapy, gene therapy, and
immunotherapy. Moreover, with some design modifications it
can be used in different organs, both externally and for internal
visceral organs.
The limitations of the current study are that it is a proof-of-
concept study and only short-term experiments were performed.
A study evaluating the long term effects is warranted to elucidate
the effect of electrospray mediated chemotherapy on tumor
recurrence. Since it was a feasibility study, we did not perform
a control group where the chemotherapeutics were administered
systemically due to 3R regulations. However, a study using a large
animal model will be a better approach to further validate the data
obtained in the current study. In conclusion, electrospray is a
promising technique for localized and targeted chemotherapy.
With further modifications of the device and application
parameters, electrospray could be a very useful tool for
minimally invasive localized therapy of intraluminal tumors,
using a bronchoscope.
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